BACKGROUND Gastrointestinal (GI) bleeding is a common complication of oral anticoagulation.
were at moderate to high risk for stroke (4) . ROCKET AF demonstrated that rivaroxaban was noninferior to warfarin for the prevention of stroke and systemic embolism (5), and rates of major and nonmajor clinically relevant bleeding were similar between treatment arms in the study. Patients randomized to rivaroxaban had fewer intracranial hemorrhages compared with warfarin, but they had significantly more GI bleeding (6) . The objectives of this retrospective analysis were to investigate the incidence and severity of GI bleeding, the factors associated with GI bleeding, and antithrombotic management of GI bleeding in the ROCKET AF trial.
METHODS
The ROCKET AF trial design and primary results have been previously published (4, 5) . Briefly, ROCKET AF was a double-blind, double-dummy, international noninferiority trial that compared oncedaily rivaroxaban versus dose-adjusted warfarin for the prevention of stroke or systemic embolism in patients with nonvalvular AF. Patients had to have previous stroke or transient ischemic attack or $2 risk factors for stroke. Patients with only 2 risk factors were capped at 10% of the overall trial population, although the observed proportion of these patients in the trial was 13%. The primary endpoint was stroke or noncentral nervous system embolism.
Patients were monitored no less than once every 4 weeks.
STUDY POPULATION.
We included all patients in the on-treatment (or "safety") population of the ROCKET AF trial, which included those who were randomized and received at least 1 dose of the study drug.
OUTCOMES. The primary safety outcomes for the ROCKET AF trial were major and nonmajor clinically relevant bleeding. In this study, we focused on adjudicated GI bleeding reported during the safety period (from first drug dose to last dose þ 2 days). All bleeds were adjudicated by a multispecialty clinical events committee blinded to the patients' treatment assignments. GI bleeding events included upper GI, lower GI, and rectal bleeding. GI bleeding was further categorized by event classification: the composite principal safety endpoint (major or nonmajor clinically relevant bleeding); major bleeding; major bleeding with a hemoglobin drop of $2 g/dl; major bleeding with transfusion; major bleeding with received a research grant from Jansen, Bayer, and AstraZeneca; and has served on the advisory board or as a consultant for Bayer, Janssen, Genzyme, and Merck. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. David Cannom, MD, served as Guest Editor for this paper.
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transfusion of $4 U of whole blood or packed red blood cells (PRBCs); major bleeding that was fatal; and nonmajor clinically relevant bleeding.
In the outcomes analyses, only the first GI bleed of each type for each patient was considered. For summaries of drug discontinuation and resumption, only the last GI bleed of any kind for each patient was considered. Permanent discontinuation of study drug was defined as the last dose received on the day of, or 1 or 2 days after, the patient's last GI bleed. Patients who died within this timeframe were not considered discontinuations. All events that occurred while patients received the study drug until 2 days after the last dose of the study drug were included in the analyses. Fatal bleeding events were those that resulted in death within 30 days of a qualifying bleeding event. Table 1) . Compared with patients who did not have GI bleeding, patients with GI bleeding were less often female, slightly older (median age of 75 years), and more likely to have used VKAs previously. There was greater prevalence of renal insufficiency, diabetes, and hypertension in the GI bleeding population, but these patients less often had a history of thromboembolic events. Patients with GI bleeding in the trial were more likely to have had a history of GI bleeding, and there was an increased prevalence of sleep apnea, chronic obstructive pulmonary disease, and history of cigarette smoking in the GI bleeding group compared with patients without GI bleeding.
The mean CHADS 2 , CHA 2 DS 2 -VASc, and HAS-BLED scores were similar in patients with and without GI bleeding. The pre-randomization use of aspirin or NSAIDs was more common in patients with GI bleeding. The use of PPIs and H2 antagonists was also higher among patients with GI bleeding compared with those without GI bleeding. For patients who
experienced GI bleeding during trial follow-up, the baseline clinical characteristics were similar between treatment arms (Online Table 1 ).
GI bleeding events were distributed in the following frequencies: 48% in the upper GI tract, 23%
in the lower GI tract, and 29% in rectal locations.
These frequencies were similar between warfarinand rivaroxaban-treated patients ( Table 2) .
OUTCOMES. There were significantly more GI bleeding events in rivaroxaban-treated patients versus warfarin-treated patients (3.61 events/100 patient-years vs. 2.60 events/100 patient-years; HR: After multivariable adjustment for clinical characteristics, patients who received rivaroxaban had a significantly higher hazard for both major and nonmajor clinically relevant GI bleeding compared with patients who received warfarin. This extended to the subgroups of major bleeding, including GI bleeds that involved a hemoglobin drop of $2 g/dl, and GI bleeds that required transfusion, but this was not significant for fatal GI bleeds or in those who required $4 U of RBC transfusion ( Table 3) .
STUDY DRUG AND ANTIPLATELET THERAPY MANAGEMENT
IN THE SETTING OF GI BLEEDING. The decision to re-start or permanently withdraw the study drug after resolution of a bleeding event was left to the discretion of the investigator according to local practice. In the setting of GI bleeding, 34% of patients remained on the study drug (21.1% of major, 47.9% of nonmajor clinically relevant bleeding), whereas 27% permanently discontinued the study drug either at the time of bleeding or 1 to 2 days previously ( Table 4) . Patients with major GI bleeding had higher rates of permanent discontinuation compared with those with nonmajor clinically relevant GI bleeding (27.6% vs. 10.7%). A total of 39% of patients stopped the study drug at or near the time of GI bleed and re-started the study drug afterward, with a median duration of interruption of 9 days.
There was a similar frequency of study drug re-start in patients with major versus nonmajor clinically relevant GI bleeding (38.5% vs. 39.6%), although the median duration of interruption was shorter in Continued on the next page Sherwood et al.
patients with nonmajor clinically relevant GI bleeding (16 vs. 7 days). Of patients who had a GI bleed, 37.8% were on aspirin before their event, whereas 15.5% were on another antiplatelet agent before their event. Nearly one-half of these patients remained on antiplatelet therapy during their GI bleed, whereas the remaining patients stopped antiplatelet agent use, and the majority of these patients stopped taking this therapy permanently.
Patterns of discontinuation of aspirin and antiplatelet agents were similar for major and nonmajor clinically relevant GI bleeding and were also similar across treatment groups (Online Tables 2 and 3 ).
FACTORS ASSOCIATED WITH GI BLEEDING. As shown in Table 5 , multivariable modeling was used to identify clinical factors associated with GI bleeding.
The factors most strongly associated with GI bleeding were anemia at baseline, a history of GI bleeding, long-term aspirin use, and rivaroxaban use (vs. p < 0.001). NA patients also had significantly higher rates of GI bleeding in both treatment arms compared with the ROW patients ( Table 6 ). After adjustment for clinical risk factors, including concomitant antiplatelet medications, patients in NA who received rivaroxaban had a significantly higher hazard for GI bleeding than those on warfarin (p for interaction ¼ 0.0069). There were also greater rates of overall bleeding in NA versus ROW patients, but no statistically significant interaction was found between geographic location and treatment assignment for overall bleeding (Online Table 5 ). The anatomic location of GI bleeding was significantly different between NA and ROW patients, with a substantially greater proportion of GI bleeds in NA stemming from a lower GI location (30% vs. 19%) and substantially fewer GI bleeds proportionally from an upper GI location (38% vs. 53%) compared with ROW patients (Online Table 6 ). Use of antiplatelet agents was similar among patients from NA compared with ROW, both at baseline (37% vs. 40%) and during follow-up (42% vs. 43%) (Online Table 7 ).
DISCUSSION
In a large, contemporary trial of moderate-to high-risk patients with nonvalvular AF who received OAC, rivaroxaban increased the rates of both major and nonmajor clinically relevant GI bleeding compared with warfarin (Central Illustration). Rates of the most severe GI bleeding, including those that were fatal and in patients who required $4-U RBC transfusion, were very low and similar between rivaroxaban-and warfarin-treated patients. Factors associated with GI bleeding in patients on warfarin or rivaroxaban were similar to previously established risk factors for GI Values are median (25th, 75th percentiles), n (%), or mean AE SD. *Calculated using the Cockcroft-Gault equation.
AF ¼ atrial fibrillation; ASA ¼ aspirin; BMI ¼ body mass index; BP ¼ blood pressure; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke or TIA or thromboembolism -vascular disease, age 65-74 years, sex category; CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, prior stroke or TIA; COPD ¼ chronic obstructive pulmonary disorder; GI ¼ gastrointestinal; HAS-BLED ¼ hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol; HF ¼ heart failure; MI ¼ myocardial infarction; NSAID ¼ nonsteroidal anti-inflammatory drug; PAD ¼ peripheral artery disease; PPI ¼ proton-pump inhibitor; TIA ¼ transient ischemic attack; VKA ¼ vitamin K antagonist. Values are n (%).
GI ¼ gastrointestinal.
bleeding. These results highlight a small but definite risk for GI bleeding that might be attenuated by minimizing concomitant risk factors. Table 5) .
RISK OF GI BLEEDING WITH
CI ¼ confidence interval; other abbreviation as in Table 1 . This system actively pumps drugs into the GI tract, allowing for greater concentrations of the active agent to remain in the gut. Dabigatran has limited bioavailability (7.2%) and is directly activated in the GI tract, which allows for prolonged exposure to an active anticoagulant compound. It also has tartaric acid in the compound, which is thought to contribute to dyspepsia. In this scenario, surface lesions in the GI tract, with prolonged exposure to an active anticoagulant compound, may be more likely to bleed. In comparison, warfarin has extremely high bioavailability and is absorbed fully from the gut, because the unabsorbed form of warfarin is inactive (16) .
Although this may explain the differential GI bleeding risk seen with dabigatran compared with warfarin, it does not explain the differential GI bleeding risk seen between the factor Xa agents. Rivaroxaban-treated patients had higher rates of major and minor gastrointestinal (GI) bleeding events compared with warfarin-treated patients; however, rates of the most severe GI bleeding events, including those that required transfusion of packed red blood cells and those that resulted in death, were comparable between treatment groups.
Apixaban, rivaroxaban, and edoxaban all have >50% bioavailability; therefore, the less active compound is allowed to pass through the gut. The elevated GI bleeding rates seen with rivaroxaban and edoxaban may be due to differential dose and pharmacokinetics of these drugs compared with apixaban.
Further investigation is necessary to understand this phenomenon. bleeding events (19) . In the aforementioned net Abbreviations as in Tables 1 and 3 . There was no interaction between treatment assignment and predictors of GI bleeding; thus, the risk predictors found in our study would have utility in both warfarin-and rivaroxaban-treated patients. However, there are few treatment Tables 1 and 3 . There are no data available for NOACs in this challenging situation (24) , but the rates of discontinuation of OAC, even in the setting of nonmajor clinically relevant bleeding, were high in our study.
RISK FACTOR MODIFICATION FOR GI
The interplay of bleeding risk factors with thrombotic risk factors creates a challenging situation for clinicians. Further investigation is necessary to provide adequate anticoagulation strategies for complex patients with thrombotic risk and risk for GI bleeding.
Geographic variation in GI bleeding rates and hazards was seen in our study population, even after multivariable adjustment for differences in clinical risk factors and differential use of antiplatelet agents. This is not easily explained, but there was more overall bleeding seen in NA versus ROW patients. In addition, the anatomic location of bleeding was more often in the lower GI tract in NA than in the ROW. This may be due to disparate practice patterns and more aggressive screening for anemia and lower GI malignancy in NA compared with other geographic regions, which may partly explain the higher reported rates of bleeding.
STUDY LIMITATIONS. First, this was a post-hoc, nonrandomized, subgroup analysis of the ROCKET AF trial. As such, the study was not powered for comparison of clinical outcomes in the GI bleeding population of the trial. Also, we had only limited data on management of the GI bleeds. Finally, inclusion and exclusion criteria for the ROCKET AF trial created a select population of moderate-to high-risk patients; thus, findings for GI bleeding risk may not be generalizable to a broader population of patients.
CONCLUSIONS
In the ROCKET AF trial, both major and nonmajor clinically relevant GI bleeding events were more frequent in patients taking rivaroxaban compared with warfarin. The most severe bleeding events, such as those that required transfusion of $4 U of RBCs or those that caused death were balanced between treatment groups. The absolute fatality rate from GI bleeding events was very low in both treatment arms.
Our results further highlight the importance of the risk and benefit consideration of OAC in patients at risk for GI bleeding and illustrate the need for minimizing modifiable risk factors for GI bleeds. 
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